BRISTOL-MYERS SQUIBB COMPANY Buildings and Improvements, Gross
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Buildings and Improvements, Gross of $7.93 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:BuildingsAndImprovementsGross · last filed 2026-07-30
- 2026-06-30: Buildings and Improvements, Gross $7.93B.
- 2026-03-31: Buildings and Improvements, Gross $7.49B.
- 2025-12-31: Buildings and Improvements, Gross $7.27B.
- 2025-09-30: Buildings and Improvements, Gross $7.12B.
| Period end | Buildings and Improvements, Gross |
|---|---|
| 2026-06-30 | $7.93B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $7.49B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $7.27B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $7.12B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $6.86B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $6.64B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $6.58B 10-K · filed 2026-02-11 |
| 2024-09-30 | $6.47B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $6.67B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $6.55B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $6.50B 10-K · filed 2025-02-12 |
| 2023-09-30 | $6.28B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $6.04B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $5.99B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $5.92B 10-K · filed 2024-02-13 |
| 2022-09-30 | $5.75B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $5.74B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $5.94B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $5.90B 10-K · filed 2023-02-14 |
| 2021-09-30 | $5.74B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $5.71B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $5.61B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $5.73B 10-K · filed 2022-02-09 |
| 2020-09-30 | $5.71B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.64B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.85B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $6.34B 10-K · filed 2021-02-10 |
| 2019-09-30 | $5.29B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $5.26B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $5.29B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $5.23B 10-K · filed 2020-02-24 |
| 2017-12-31 | $4.85B 10-K · filed 2019-02-25 |
| 2016-12-31 | $4.93B 10-K · filed 2018-02-13 |
| 2015-12-31 | $4.51B 10-K · filed 2017-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |